Study on the efficacy of 5ASA oral formula and suppository against relapse of proctitis
Not Applicable
- Conditions
- proctitis
- Registration Number
- JPRN-UMIN000014838
- Lead Sponsor
- TT Medical Center Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnant or nursing female Patients who received steroids, immunosuppressants, immunomodulators, anti-TNF alpha, or leucocytapheresis within 3 months before the study entry Those with severe liver or renal dysfunction Those with a history of hypersensitivity against mesalazine Those who were regarded inadequate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement in endoscopic Mayo score 4 weeks after the intervention
- Secondary Outcome Measures
Name Time Method proportion of patients without relapse of rectal bleeding after 1 year of maintenance therapy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 5ASA's anti-inflammatory effects in proctitis relapse prevention?
How does oral 5ASA compare to rectal suppository 5ASA in efficacy for ulcerative proctitis maintenance therapy?
Which biomarkers correlate with 5ASA treatment response in patients with idiopathic proctitis?
What adverse events are associated with long-term 5ASA use in proctitis management and how are they managed?
Are there combination therapies involving 5ASA and immunomodulators for refractory proctitis treatment?